US Stock Market Closed

Dashboard

CNS Pharmaceuticals, Inc. (CNSP)

Current

- (-)

After Hours

Rating & Fair Value

Fair Value Premium lock
Institutional Holdings

H

Financial Strength

H

Sustainable Growth

S

Industry Comparison

H

Management & Equity
Analyst Opinion

H

Leverage & Liquidity

H

Fundamental Variables

Rating Performance

FV Performance

About

CNS Pharmaceuticals, Inc. is a preclinical stage pharmaceutical company, which engages in the development of anticancer drug candidates for the treatment of primary and metastatic brain and central nervous system tumors. Its product pipeline includes berubicin, and CNS-12. The company was founded by Waldemar Priebe in July 2017 and is headquartered in Houston, TX.

CEO

John M. Climaco

Employees

5

Industry

-

Sector

-

Headquarters

Houston

Exchange

NASDAQ

Summary Stats

Market Cap

11.1M

Revenue

-

Net Income

-

EPS

$0.00

Price-to-Earnings

-

Price-to-Book

-

Debt-to-Equity

-

News

Analyst Ratings

Price targets projected by 2 analysts

High

$11.00

Average

$9.50

Low

$8.00

Ratings calculated by 1 analyst

Buy

1

Hold

0

Sell

0

Last Dividend

Amount

-

Dividend Date

-

Frequency

-

Dividend Yield

Earnings

Most Recent Earnings

Last Earnings for Q1 2022

Last Earnings

Above by $0.04

Actual

-$0.07 +36.4%

Consensus

-0.11

Report Date

Year Ago

-0.15

Year Ago Change %

Up 53%

Actual vs Estimates

XX

xxx

Upcoming Estimates Unavailable

Expected EPS
-

-

Actual EPS
-

--

Competitors

star Favorites